Recombinant Human TGF-beta RI/ALK-5 Fc Avi-tag Protein, CF

When Recombinant Human TGF-beta RII Fc Chimera (341-BR) is immobilized at 1 μg/mL (100 μL/well), in the presence of Recombinant Human TGF-beta 1 (240-B), it binds Recombinant Human TGF-beta RI/ALK-5 Fc Chimera Avi-tag (Catalog # AVI3025) with an ED50 of 0.15-0.75 μg/mL.

2 μg/lane of Biotinylated Recombinant Human TGF-beta RI/ALK-5 Fc Chimera Avi-tag (Catalog # AVI3025) was resolved with SDS-PAGE under reducing (R) and non-reducing (NR) conditions and visualized by Coomassie® Blue staining, showing bands at 43-60 kDa and 86-120 kDa, respectively

• Reactivity: Hu
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Human TGF-beta RI/ALK-5 Fc Avi-tag Protein, CF Summary

• Additional Information: Biotinylated
• Details of Functionality: The biotin to protein ratio is greater than 0.7 as determined by the HABA assay. Measured by its binding ability in a functional ELISA. When Recombinant Human (rh) TGF-beta RII Fc Chimera (Catalog # 341-BR) is immobilized at 1 μg/mL (100 μL/well), in the presence of rhTGF‑ beta 1 (Catalog # 240-B), Biotinylated Recombinant Human TGF‑ beta RI/ALK-5 Fc Chimera Avi-tag protein binds with an ED₅₀ of 0.15‑0.75 μg/mL.
• Source: Human embryonic kidney cell, HEK293-derived human TGF-beta RI/ALK-5 protein
  

  Human TGF-beta R1/ALK-5 (Ala25 or Leu34-Glu125) Accession # P36897.1	IEGRMD	Human IgG1 (Pro100-Lys330)	Avi-tag
  N-terminus			C-terminus

• Accession #: P36897.1
• N-terminal Sequence: Ala25, Leu34
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
  • Bioactivity2
• Theoretical MW: 39 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 43-60 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS with Trehalose.
• Purity: >95%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Human TGF-beta RI/ALK-5 Fc Avi-tag Protein, CF

• AAT5
• activin A receptor type II-like kinase, 53kD
• activin A receptor type II-like kinase, 53kDa
• Activin receptor-like kinase 5
• ACVRLK4
• ALK-5
• ALK-5ALK5
• EC 2.7.11
• EC 2.7.11.30
• LDS1A
• LDS2A
• Serine/threonine-protein kinase receptor R4
• SKR4
• tbetaR-I
• TGFB1R1
• TGF-beta receptor type I
• TGF-beta receptor type-1
• TGF-beta RI
• TGF-beta type I receptor
• TGFbetaRI
• TGFBR1
• TGF-bRI
• TGFR-1
• transforming growth factor beta receptor I
• transforming growth factor, beta receptor 1
• transforming growth factor, beta receptor I (activin A receptor type II-likekinase, 53kD)
• Transforming growth factor-beta receptor type I

Background

TGF-beta RI, also called ALK-5, is an approximately 55 kDa type I transmembrane serine/threonine receptor kinase (1, 2). It contains a cysteine-rich extracellular domain (ECD), a transmembrane helix, and a C-terminal cytoplasmic kinase domain (3). Within the cytoplasmic domain there is also a short, conserved regulatory sequence known as the GS region that is N-terminal to the kinase domain (1). Within the ECD, human TGF-beta RI shares 90% and 88% aa sequence identity with mouse and rat TGF-beta RI, respectively. In the presence of TGF-beta , TGF-beta RI forms a complex with, and is phosphorylated by, TGF-beta RII (1). Phosphorylated TGF-beta RI can then transiently bind and phosphorylate Smad2 and Smad3 (2, 4-6). These phosphorylated Smads form heteromeric complexes with Smad4, translocate to the nucleus, and regulate target gene transcription (2, 4-6). TGF-beta RI is likely important during development, since mice deficient for TGF-beta RI die at midgestation with severe defects in vascular development of the yolk sac and placenta, and an absence of circulating red blood cells (7). Furthermore, TGF-beta RI appears to be involved in proper lymphatic network development (8). Mutations in TGF-beta RI have been identified in pancreatic, colorectal, ovarian, and head and neck cancers (9). Our Avi-tg Biotinylated human TGF-beta RI features biotinylation at a single site contained within the Avi-tag, a unique 15 amino acid peptide. Protein orientation will be uniform when bound to streptavidin-coated surface due to the precise control of biotinylation and the rest of the protein is unchanged so there is no interference in the protein's bioactivity.

1. Wrana, J.L. et al. (1994) Nature 370:341.
2. Massagué, J. (2012) Nat. Rev. Mol. Cell Biol. 13:616.
3. Huse, M. et al. (1999) Cell 96:425.
4. Marcías-Silva, M. et al. (1996) Cell 87:1215.
5. Zhang, Y. et al. (1996) Nature 383:168.
6. Huse, M. et al. (2001) Mol. Cell 8:671.
7. Larsson, J. et al. (2001) EMBO J. 20:1663.
8. James, J.M. et al. (2013) Development 140:3903.
9. Sheen, Y.Y. et al. (2013) Biomol. Ther. (Seoul) 21:323.

Bioinformatics

• Uniprot:
  • P36897.1()